Scor SE · EURONEXT:SCR

Scor — Technical Presentation (June 2022)

32 slides from Scor's technical presentation, June 2022

  1. Slide 1: Human Genetics of Tuberculosis

    Human Genetics of Tuberculosis Laurent Abel Laboratory of Human Genetics of Infectious Diseases INSERM/ Université Paris Cité U.1163 Imagine Institute, Necker, Paris, France The Rockefeller University, New-York, USA

  2. Slide 2: Tuberculosis (TB): Major public health problem

    Tuberculosis (TB): Major public health problem ~ 1/3 world’s population exposed to Mycobacterium tuberculosis ~ 10 million new cases/year and ~ 2 million deaths/year Increasing drug resistant (MDR and XDR) strains ~ 10% of infected individuals develop clinical disease → Pathogenesis of TB?

  3. Slide 3: Variability of response to exposure and infection

    Variability of response to exposure and infection MYCOBACTERIA EXPOSURE VIRULENCE PRIMARY TB ~5% (Extra-pulmonary) ~90% M. tuberculosis INFECTION ~5% REACTIVATION TB (Pulmonary) NON-GENETIC (Acquired GENETIC Immunodeficiency) HOST

  4. Slide 4: TB: Individual variability in clinical outcomes

    TB: Individual variability in clinical outcomes 60 Mortality per 100,000 50 generalized TB pulmonary TB 40 30 20 10 0 over 70 0--1 1--2 3--5 6--10 11--15 16--20 21--30 31--40 41--50 51--60 61--70 years Ranke, K. 1910. Diagnose und Epidemiologie der Lungentuberculose des Kindes. Archiv für Kinderheil

  5. Slide 5: Familial (twin) studies (1930s)

    Familial (twin) studies (1930s)

  6. Slide 6: Human genetics of tuberculosis

    Human genetics of tuberculosis Why do some exposed individuals (and not others) get infected and develop tuberculosis? What are the critical immunological pathways in natural conditions of infection? → Search of genetic variants that: - may explain differences between individuals (in part) - are inf

  7. Slide 7: Considerable number of genetic variants

    Considerable number of genetic variants Human genome is > 3000 millions base pairs (A, T, C, G) > 300 million reported variants in humans (most of them are <1%) Most frequent variants are single nucleotide polymorphisms (SNPs) (simple change of one base to another, eg from A to G)

  8. Slide 8: Methods of investigation in humans

    Methods of investigation in humans How to identify the causal genetic variant? Phenotype Rare: Disseminated TB Common: Pulmonary TB (children) (adults) Tools Mendelian Genetics Complex Genetics Sample Small Large Rare mutations Common polymorphisms Strong individual effect Modest individual effect U

  9. Slide 9: Genetic architecture of TB

    Genetic architecture of TB → Continous spectrum of predisposition according to individual effect and frequency of genetic variant Relative risk (odds ratio, OR) (Manolio et al, Nature, 2009)

  10. Slide 10: Genetic susceptibility to TB depends on age?

    Genetic susceptibility to TB depends on age? Childhood TB (disseminated) Adult PulmonaryTB Search for rare mutations Search for common variants with strong individual impact with modest individual effect → Mendelian/Monogenic TB Very limited success

  11. Slide 11: Genetic susceptibility to TB depends on age?

    Genetic susceptibility to TB depends on age? Childhood TB (disseminated) Adult PulmonaryTB Search for rare mutations Search for common variants with strong individual impact with modest individual effect → Mendelian/Monogenic TB Very limited success

  12. Slide 12: Genetic susceptibility to TB depends on age?

    Genetic susceptibility to TB depends on age? Childhood TB (disseminated) Adult PulmonaryTB Search for rare mutations Search for common variants with strong individual impact with modest individual effect → Mendelian/Monogenic TB Very limited success

  13. Slide 13: Mendelian Susceptibility to Mycobacterial Disease (MSMD)

    Mendelian Susceptibility to Mycobacterial Disease (MSMD) • Rare syndrome: 1/100,000 • Infections by BCG and environmental mycobacteria • Otherwise healthy individuals • Familial forms and parental consanguinity frequent BCGitis Poor granulomatous Disseminated M. avium reaction infection

  14. Slide 14: MSMD: genetic defects in IL-12/-23/IFN-γ pathway

    MSMD: genetic defects in IL-12/-23 /IFN-γ pathway

  15. Slide 15: MSMD: genetic defects in IL-12/-23/IFN-γ pathway

    MSMD: genetic defects in IL-12/-23 /IFN-γ pathway  Impaired response to IFN-γ

  16. Slide 16: MSMD: genetic defects in IL-12/-23/IFN-γ pathway

    MSMD: genetic defects in IL-12/-23 /IFN-γ pathway  Impaired production of IFN-γ (amenable to IFN-γ treatment)

  17. Slide 17: First evidence of Mendelian TB

    First evidence of Mendelian TB → Complete autosomal recessive (AR) IL-12Rβ1 deficiency MSMD Abdominal TB

  18. Slide 18: Mendelian TB: Candidate gene IL12RB1

    Mendelian TB → Candidate gene : IL12RB1 50 TB severe children patients from Turkey, Iran and Morocco → Identification of TWO patients with complete autosomal recessive (AR) IL-12Rβ1 deficiency K305X/WT K305X/WT From Morocco BCG vaccinated at birth (no adverse effect) K305X/K305X Severe pulmonary TB

  19. Slide 19: From rare to common monogenic causes of TB: TYK2 deficiency

    From rare to common monogenic causes of TB: TYK2 deficiency

  20. Slide 20: AR TYK2 complete deficiency in new families

    AR TYK2 complete deficiency in 4 new families Minegishi et al. Immunity 2006 Kreins et al J Exp Med 2015

  21. Slide 21: AR TYK2 complete deficiency in new families

    AR TYK2 complete deficiency in 4 new families Abdominal TB Miliary

  22. Slide 22: Investigation of a more common TYK2 variant: P1104A

    Investigation of a more common TYK2 variant: P1104A In our exome database of >6000 subjects: 11 P1104A homozygotes including 10 EUR in mycobacterial diseases: AFR - 7 in TB (out of 455 patients) AMR - 3 in MSMD (out of 463 patients) - 1 in other conditions (out of 5359) S. ASIA Highly significant wh

  23. Slide 23: Worldwide P1104A frequency

    Worldwide P1104A frequency 0.040 0.018 0.031 5x10-5 0.011 0.012 <10-3 Gnomad MAF by region MAF by country

  24. Slide 24: Impaired response to IL-23

    Impaired response to IL-23 Impaired response to IL-23 for P1104A homozygotes Impaired IFN-γ production in EBV-B cells in response to IL-23 in whole blood → Impairment of IL-23 mediated IFN-γ immunity

  25. Slide 25: Replication in the UK Biobank data

    Replication in the UK Biobank data

  26. Slide 26: Enrichment of P1104A homozygotes in TB

    Enrichment of P1104A homozygotes in TB GWAS array with imputed data. Doctor-diagnosed TB: 620 with TB and 114,473 without P1104A TB Controls Homozygous 6 (1%) 228 (0.2%) Non homozygous 614 114,245 Odd ratio of developing TB adjusted for ethnic origin: OR= 5.0 (1.96-10.31), p=0.002 Kerner et al PNAS

  27. Slide 27: TYK2 P1104A: Population genetic studies

    TYK2 P1104A: Population genetic studies (Quintana-Murci lab) TB has killed more than any other infectious disease during the last 200 years → Selection pressure exerted by TB WHO, 2020; Paulson T. Nature 2013

  28. Slide 28: Frequency of P1104A

    Frequency of P1104A Using ~1000 ancient DNAs Origin of P1104A ~30,000 yrs ago Strong negative selection Increase in frequency until 2000-3000 BC starting ~2000 yrs ago Strong decline since then

  29. Slide 29: Conclusions

    Conclusions Recessive TYK2 P1104A condition represents a common monogenic etiology of TB It may underlie TB in about 1% of Europeans (up to 0.5% elsewhere except East Asia and Subsaharan Africa) Blurs the dichotomy between rare monogenic and common complex predisposition P1104A selectively impairs I

  30. Slide 30: Laboratory of Human Genetics of Infectious Diseases

    Alexandre Alcaïs S. Boisson-Dupuis Jacinta C. Bustamante Xiao-Fei Kong Aurélie Cobat Alexandra Kreins Clement Conil Masato Ogishi Gaspard Kerner Quentin Philipot Jeremy Manry Rui Yang Laboratory of Human Genetics of Infectious Diseases Jean-Laurent Casanova and Laurent Abel

  31. Slide 31: Huge number of collaborators

    Huge number of collaborators E. Patin, L. Quintana-Murci Pasteur Institute, Paris. S. Pellegrini Pasteur Institute, Paris. M. Orlova, E. Schurr McGill University, L. Barreiro Ste Justine,Montreal Univ. V. Rasolofo J. El Baghdadi Pasteur Institute, Antananarivo Military Hospital, Rabat A. Bousfiha, J

  32. Slide 32: Slide 32

Scor — Technical Presentation (June 2022) on 6ix